These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 33743369)

  • 1. In-vitro activity of tigecycline against multidrug-resistant Gram negative bacteria: The experience of a university hospital.
    Elnasser Z; Elsamarneh R; Obeidat H; Amarin Z; Jaradat S; Kaplan N
    J Infect Public Health; 2021 Apr; 14(4):478-483. PubMed ID: 33743369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016.
    Dowzicky MJ; Chmelařová E
    J Glob Antimicrob Resist; 2019 Jun; 17():44-52. PubMed ID: 30445209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of role of Tigecycline among clinically significant multidrug resistant pathogens from a tertiary care hospital.
    Remash A; Rao P; Shenoy S; Baliga S; Kassim S
    F1000Res; 2024; 13():36. PubMed ID: 38872735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bismuth Drugs Reverse Tet(X)-Conferred Tigecycline Resistance in Gram-Negative Bacteria.
    Deng T; Jia Y; Tong Z; Shi J; Wang Z; Liu Y
    Microbiol Spectr; 2022 Feb; 10(1):e0157821. PubMed ID: 35138168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.
    Vouillamoz J; Moreillon P; Giddey M; Entenza JM
    J Antimicrob Chemother; 2008 Feb; 61(2):371-4. PubMed ID: 18033780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
    Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
    J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Morrissey I; Olesky M; Hawser S; Lob SH; Karlowsky JA; Corey GR; Bassetti M; Fyfe C
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of tigecycline and comparators against gram-negative bacteria isolated from a tertiary hospital in Alexandria, Egypt.
    Mohamed NM; Youssef AA
    Microb Drug Resist; 2011 Dec; 17(4):489-95. PubMed ID: 21875338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014.
    Tärnberg M; Nilsson LE; Dowzicky MJ
    Int J Infect Dis; 2016 Aug; 49():141-8. PubMed ID: 27343986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence and characterization of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae isolates from blood samples of patients in intensive care units in northern China.
    Xu H; Zhou Y; Zhai X; Du Z; Wu H; Han Y; Huo C; Chen Y
    J Med Microbiol; 2016 Aug; 65(8):751-759. PubMed ID: 27324378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline for treatment of multidrug-resistant gram-negative bacteria in transplant recipient patients: Challenges of antimicrobial susceptibility testing.
    Sfeir MM
    Transpl Infect Dis; 2020 Apr; 22(2):e13254. PubMed ID: 32017304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.